Back to top
more

Nivalis Therapeutics, Inc. (ALPN)

(Delayed Data from NSDQ)

$6.24 USD

6.24
7,474

-0.08 (-1.27%)

Updated May 3, 2019 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

2 items in cart

View Cart/Checkout

[ALPN]

Reports for Purchase

Showing records 101 - 120 ( 156 total )

Industry: Medical - Drugs

Record: 101

06/07/2021

Company Report

Pages: 7

ALPN-202''s Future Appears Luminous with First Look at NEON-1

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 102

06/03/2021

Company Report

Pages: 8

Evidence Builds for ALPN-303?s Differentiated Profile in B Cell Indications

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 103

05/21/2021

Industry Report

Pages: 19

ASCO 2021 Abstract Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 104

05/20/2021

Company Report

Pages: 6

ALPN-202 Makes Its Debut with Promising Data at ASCO

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 105

05/17/2021

Company Report

Pages: 7

Q1 Financials; First Look at ALPN-202 Ahead

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 106

05/17/2021

Daily Note

Pages: 11

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 107

05/14/2021

Company Report

Pages: 6

1Q21 Results; Pipeline Humming Along Nicely; Key Update at ASCO

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 108

05/11/2021

Company Report

Pages: 7

Investor Meetings Solidify Opportunities; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 109

04/14/2021

Industry Report

Pages: 33

Takeaways from 2021 AACR Virtual Meeting

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 110

03/22/2021

Company Report

Pages: 6

Q4 Financials; SLE Ph 2 to Initiate Mid-Year; ?202 Data at ASCO

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 111

03/19/2021

Company Report

Pages: 6

2020 Results; Active Clinical Pipeline Takes Center Stage for Upcoming Year

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 112

03/15/2021

Industry Report

Pages: 16

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 113

12/21/2020

Company Report

Pages: 25

Targeting the Immune System From All Angles; Initiating at Buy and $21 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 75.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 114

11/13/2020

Company Report

Pages: 5

Q3 Financials; SLE Study to Commence in 1H:21

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 115

11/08/2020

Industry Report

Pages: 13

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 116

08/13/2020

Company Report

Pages: 6

Q2 Financials; ALPN Well Positioned as NEON Study Continues Enrollment

Provider: WEDBUSH SECURITIES INC.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 117

08/10/2020

Industry Report

Pages: 11

HEALTHCARE -The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 118

08/09/2020

Daily Note

Pages: 11

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 119

07/01/2020

Industry Report

Pages: 18

The Wedbush Monthly Check-Up: July 2020

Provider: WEDBUSH SECURITIES INC.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 120

06/25/2020

Industry Report

Pages: 45

AACR II 2020 Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 100.00

Research Provided by a Third Party